MARKET

NVCR

NVCR

Novocure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

72.60
-4.48
-5.81%
Opening 15:21 05/24 EDT
OPEN
75.74
PREV CLOSE
77.08
HIGH
75.74
LOW
72.60
VOLUME
204.21K
TURNOVER
10.42M
52 WEEK HIGH
232.76
52 WEEK LOW
56.51
MARKET CAP
7.59B
P/E (TTM)
-127.9746
1D
5D
1M
3M
1Y
5Y
Are Investors Undervaluing NovoCure Limited (NASDAQ:NVCR) By 47%?
Does the May share price for NovoCure Limited ( NASDAQ:NVCR ) reflect what it's really worth? Today, we will estimate...
Simply Wall St. · 1d ago
NovoCure initiated at buy at Wainwright on base business expansion, phase 3 readouts
H.C. Wainwright has initiated NovoCure (NASDAQ:NVCR) with a buy rating citing international expansion of its core business and four phase 3 studies with readouts expected from 2022-2024. The firm has
Seekingalpha · 05/16 17:10
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022
Upgrades
Benzinga · 05/16 14:04
NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT Newswires · 05/16 13:25
HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT Newswires · 05/16 06:50
Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight Rating
MT Newswires · 05/13 06:36
AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remov...
GlobeNewswire · 05/12 17:00
Looking Into NovoCure's Return On Capital Employed
According to data from Benzinga Pro, during Q1, NovoCure's (NASDAQ:NVCR) reported sales totaled $137.55 million. Despite a 82.44% increase in earnings, the company posted a loss of $4.65 million.
Benzinga · 05/05 13:56
More
No Data
Learn about the latest financial forecast of NVCR. Analyze the recent business situations of Novocure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.11%Strong Buy
44.44%Buy
33.33%Hold
0.00%Under-perform
11.11%Sell
Analyst Price Target
The average NVCR stock price target is 102.75 with a high estimate of 200.00 and a low estimate of 45.00.
High200.00
Average102.75
Low45.00
Current 73.59
EPS
Actual
Estimate
-0.20-0.14-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 421
Institutional Holdings: 83.91M
% Owned: 80.23%
Shares Outstanding: 104.59M
TypeInstitutionsShares
Increased
89
5.17M
New
45
548.40K
Decreased
112
2.63M
Sold Out
49
689.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.37%
Healthcare Equipment & Supplies
-0.64%
Key Executives
Chairman/Executive Director
William Doyle
President/Chief Executive Officer/Director
Asaf Danziger
Chief Financial Officer
Ashley Cordova
Corporate Executive
Ely Benaim
Chief Operating Officer
Wilhelmus Groenhuysen
Chief Human Resource Officer
William Burke
Vice President
Michael Ambrogi
General Counsel
Todd Longsworth
Other
Frank Leonard
Other
Pritesh Shah
Lead Director/Independent Director
William Vernon
Independent Director
Jeryl Hilleman
Independent Director
David Hung
Independent Director
Kinyip Gabriel Leung
Independent Director
Martin Madden
Independent Director
Sherilyn McCoy
Independent Director
Timothy Scannell
No Data
No Data
About NVCR
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.